PureTech Health is to develop a combination of a microbiome treatment with checkpoint inhibitor immunotherapy to enhance the effect of the cancer drugs.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh